Viatris Inc (HAM:VIA)

€ 12.47 0 (0%) Market Cap: 14.94 Bil Enterprise Value: 28.20 Bil PE Ratio: 0 PB Ratio: 0.80 GF Score: 65/100

Q3 2024 Viatris Inc Earnings Call Transcript
Nov 07, 2024

€10.77 (-1.73%)

Earnings
Q2 2024 Viatris Inc Earnings Call Transcript
Aug 08, 2024

€10.6 (+0.57%)

Earnings
Q4 2023 Viatris Inc Earnings Call Transcript
Feb 28, 2024

€12.45 (+1.57%)

Earnings
Viatris Inc at JPMorgan Healthcare Conference Transcript
Jan 10, 2024
Viatris Inc at Jefferies London Healthcare Conference Transcript
Nov 15, 2023
Q3 2023 Viatris Inc Earnings Call Transcript
Nov 07, 2023

€8.55 (-0.28%)

Earnings
Q2 2023 Viatris Inc Earnings Call Transcript
Aug 07, 2023

€9.61 (+0.74%)

Earnings
Viatris Inc at Goldman Sachs Healthcare Conference Transcript
Jun 13, 2023
Q1 2023 Viatris Inc Earnings Call Transcript
May 08, 2023

€8.35 (+3.07%)

Earnings
Q4 2022 Viatris Inc Earnings Call and Investor Event Transcript
Feb 27, 2023

€10.89 (+0.59%)

Earnings
Viatris Inc at JPMorgan Healthcare Conference Transcript
Jan 11, 2023
Q3 2022 Viatris Inc Earnings Call Transcript
Nov 07, 2022

€9.62 (-2.79%)

Earnings
Viatris Inc at Bank of America Merrill Lynch Global Healthcare Conference Transcript
Sep 15, 2022
Q2 2022 Viatris Inc Earnings Call Transcript
Aug 08, 2022

€9.42 (+0.72%)

Earnings
Viatris Inc at Goldman Sachs Global Healthcare Conference Transcript
Jun 14, 2022
Q1 2022 Viatris Inc Earnings Call Transcript
May 09, 2022

€9.33 (-0.83%)

Earnings
Viatris Inc at Barclays Global Healthcare Conference Transcript
Mar 16, 2022
Viatris Inc at Raymond James Institutional Investors Conference Transcript
Mar 08, 2022
Q4 2021 Viatris Inc Earnings Call Transcript
Feb 28, 2022

€9.91 (-20.63%)

Earnings
Viatris Inc at Evercore ISI HealthCONx Virtual Conference Transcript
Dec 01, 2021
Q3 2021 Viatris Inc Earnings Call Transcript
Nov 08, 2021

€12.07 (+1.60%)

Earnings
Viatris Inc at Bank of America Global Healthcare Conference (Virtual) Transcript
Sep 15, 2021
Viatris Inc at Citi BioPharma Conference (Virtual) Transcript
Sep 10, 2021
Q2 2021 Viatris Inc Earnings Call Transcript
Aug 09, 2021

€11.87 (+1.47%)

Earnings
Viatris Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Jun 10, 2021
Viatris Inc at RBC Capital Markets Global Healthcare Conference (Virtual) Transcript
May 18, 2021
Viatris Inc at BofA Securities 2021 Health Care Conference Transcript
May 11, 2021
Q1 2021 Viatris Inc Earnings Call Transcript
May 10, 2021

€12.54 (+10.76%)

Earnings
Viatris Inc at Barclays Global Healthcare Conference (Virtual) Transcript
Mar 10, 2021
Viatris Inc Investor Day Transcript
Mar 01, 2021
Viatris Inc 2021 Financial Guidance Call Transcript
Feb 22, 2021
Viatris Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 14, 2021

Viatris Inc at Jefferies London Healthcare Conference Transcript

Nov 15, 2023 / 09:30AM GMT

Release Date Price: €8.47 (+1.83%)

Transcript

Glen Joseph Santangelo

Jefferies LLC, Research Division - Equity Analyst

Good morning, everybody. Thank you for joining us. We're excited to be hosting Viatris here with us today. Joining us from the company is Scott Smith, CEO, gentleman in the middle; to his left, Rajiv Malik, the President; and to Scott's far right over there Sanjeev Narula, the CFO; and Bill Szablewski, (inaudible) who heads Capital Market, he also (inaudible) Investor Relations (inaudible).

Today's format is just going to be a question-and-answer session. So we'll hope we'll try to get through this as fast as possible. For those of you who don't know me, I'm Glen Santangelo, I cover the specialty pharma, company operation, technology sectors at Jefferies and the analyst responsible for coverage of Viatris. So with that why don't we get started.

Questions & Answers

Glen Joseph Santangelo

Jefferies LLC, Research Division - Equity Analyst

Scott it's been an interesting 8 months since you took over as CEO, a lot going on this year. The company transformation really

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.